Premium
P2‐007: Plasma and CSF Aß for the diagnosis of Alzheimer's disease dementia and other dementias in mild cognitive impairment: A Cochrane Systematic Review
Author(s) -
Ritchie Craig,
Flicker Leon,
Smailagic Nadja,
NoelStorr Anna,
McShane Rupert
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.710
Subject(s) - dementia , cognitive impairment , medicine , disease , neuroimaging , receiver operating characteristic , alzheimer's disease , etiology , diagnostic accuracy , pathology , psychology , psychiatry
determined a value (optical density units) for pPKR that could discriminate AD patients from control subjects with a sensitivity of 91.1% and a specificity of 94.3%. Among AD patients, T-PKR and pPKR levels correlate with CSF p181tau levels. Some AD patients with normal CSF As, T-tau, or p181tau levels had abnormal T-PKR and pPKR levels. Conclusions: The evaluation of CSF T-PKR and pPKR levels can discriminate between AD patients and NDC and could help to improve the biochemical diagnosis of AD. Because PKR is pro-apoptotic and pro-inflammatory, this kinase represents a valid pharmacological target to slow the inexorable cognitive decline of AD patients.